Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study

Majumder,Khairul; Brandberg,Yvonne; Johansson,Hemming; Castellanos,Enrique; Ullén,Anders; Lennernäs,Bo; Nilsson,Sten

doi:10.3892/mco.2017.1487

Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study

Authors:
- Khairul Majumder
- Yvonne Brandberg
- Hemming Johansson
- Enrique Castellanos
- Anders Ullén
- Bo Lennernäs
- Sten Nilsson
View Affiliations

Affiliations: Department of Oncology‑Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden, Department of Oncology, Karolinska University Hospital, 171 76 Stockholm, Sweden, Department of Oncology, Örebro University Hospital, 701 85 Örebro, Sweden
Published online on: November 3, 2017 https://doi.org/10.3892/mco.2017.1487
Pages: 141-146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To avoid pubic arch interference, prostate cancer patients are treated with neoadjuvant androgen deprivation therapy (ADT) to achieve prostate volume (PV) reduction prior to radiation treatment. The aim of the present randomised study was to compare the effects on PV of two regimens of ADT, an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. Consecutive patients with non‑metastatic prostate cancer were included in a randomised neoadjuvant study, comparing an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. PV was assessed prior to the start of endocrine neoadjuvant treatment and prior to the start of radiation therapy (RT). PV assessment was performed by transrectal ultrasound. A total of 110 patients were included. Final sample constituted 88 (80%) patients due to lack of PV information. Castration plus an androgen receptor inhibitor was more effective in PV reduction compared with an androgen receptor inhibitor alone (P<0.001). Planning target volume decreased in the combination arm. There was no significant difference in clinical or demographic or length of neoadjuvant hormonal treatment between the groups. Overall, a significantly larger PV reduction was achieved by castration plus androgen receptor inhibitor, as compared with androgen receptor inhibitor monotherapy. The PV reduction, however, appeared not to translate into better health associated quality of life during the subsequently given curative intended combined EBRT and HDR‑brachytherapy. Potential differences between these two treatments regarding anti‑tumor effects on micro metastatic disease and radiation potentiating effect remains to be addressed in future prospective trials.

View Figures

View References

1	Lee WR: The role of androgen deprivation therapy combined with prostate brachytherapy. Urology. 60(3 Suppl 1): S39–S44. 2002. View Article : Google Scholar
2	Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA and Kurko B: Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology. 68:116–120. 2006. View Article : Google Scholar : PubMed/NCBI
3	Nishiyama T, Tomita Y and Takahashi K: Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging. Urology. 63:917–921. 2004. View Article : Google Scholar : PubMed/NCBI
4	Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L and Fuks Z: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostate cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 29:755–761. 1994. View Article : Google Scholar : PubMed/NCBI
5	Henderson A, Langley SM and Laing RW: Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol). 15:318–321. 2003. View Article : Google Scholar : PubMed/NCBI
6	Shearer RJ, Davies JH, Gelister JS and Dearnaley DP: Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol. 69:521–524. 1992. View Article : Google Scholar : PubMed/NCBI
7	Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD, Arjomandy B and Kassaee A: The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 44:1107–1110. 1999. View Article : Google Scholar : PubMed/NCBI
8	Carter SS, Torp-Pedersen ST and Holm HH: Ultrasound-guided implantation techniques in treatment of prostate cancer. Urol Clin North Am. 16:751–762. 1989.PubMed/NCBI
9	Rasch C, Barillot I, Remeijer P, Touw A, van Herk M and Lebesque JV: Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys. 43:57–66. 1999. View Article : Google Scholar : PubMed/NCBI
10	Badiozamani KR, Wallner K, Cavanagh W and Blasko J: Camparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys. 43:375–378. 1999. View Article : Google Scholar : PubMed/NCBI
11	Furuya R, Hisasue S, Furuya S, Saitoh N, Ogura H, Takahashi S and Tsukamoto T: Fate of seminal vesicles and prostate after medical castration: How long is the optimal duration of neoadjuvant treatment for prostate cancer before radiation? Urology. 72:417–421. 2008. View Article : Google Scholar : PubMed/NCBI
12	Majumder K, Nilsson S, Johansson H, Ullén A, Lennernäs B, Bergenmar M and Brandberg Y: Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study. Eur J Cancer. 65:43–51. 2016. View Article : Google Scholar : PubMed/NCBI
13	Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365–376. 1993. View Article : Google Scholar : PubMed/NCBI
14	van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, et al: An international field study of the EORTC QLQPR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 44:2418–2424. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J and Martinez A: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol. 167:2443–2447. 2002. View Article : Google Scholar : PubMed/NCBI
16	Alsadius D, Olsson C, Pettersson N, Tucker SL, Wilderäng U and Steineck G: Patient-reported gastrointestinal symptoms among long-term survivors after radiation therapy for prostate cancer. Radiother Oncol. 112:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
17	Gillespie C, Goode C, Hackett C and Andreyev HJ: The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther. 26:555–563. 2007. View Article : Google Scholar : PubMed/NCBI
18	Hopfgarten T, Adolfsson J, Henningsohn L, Onelöv E and Steineck G: The choice between a therapy-induced long-term symptom and shortened survival due to prostate cancer. Eur Urol. 50:280–289. 2006. View Article : Google Scholar : PubMed/NCBI
19	Andreyev HJ, Vlavianos P, Blake P, Dearnaley D, Norman AR and Tait D: Gastrointestinal symptoms after pelvic radiotherapy: Role for the gastroenterologist? Int J Radiat Oncol Biol Phys. 62:1464–1471. 2005. View Article : Google Scholar : PubMed/NCBI
20	Lilleby W, Fosså SD, Waehre HR and Olsen DR: Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 43:735–743. 1999. View Article : Google Scholar : PubMed/NCBI
21	Al-Abany M, Helgason AR, Cronqvist AK, Svensson C, Wersäll P and Steineck G: Long-term symptoms after external beam radiation therapy for prostate cancer with three or four fields. Acta Oncol. 41:532–542. 2002. View Article : Google Scholar : PubMed/NCBI